Central Valley Advisors LLC Raises Position in Enovis Corporation $ENOV

Key Points

• Central Valley Advisors LLC increased its stake in Enovis Corporation by 18.5%, owning 57,372 shares valued at approximately $1.8 million as of its latest filing with the SEC.
• CEO Damien Mcdonald and CFO Phillip Benjamin Berry purchased significant shares of Enovis, indicating a 6.71% and 2.19% increase in their respective ownership stakes.
• The company reported earnings of $0.79 per share for the quarter, exceeding expectations and showing a 7.5% increase in revenue from the previous year.

Central Valley Advisors LLC increased its position in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 18.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,372 shares of the company's stock after purchasing an additional 8,951 shares during the period. Central Valley Advisors LLC owned approximately 0.10% of Enovis worth $1,799,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in ENOV. Farther Finance Advisors LLC increased its stake in shares of Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock valued at $27,000 after purchasing an additional 536 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Enovis by 144.8% in the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after acquiring an additional 692 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Enovis by 57.7% in the first quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company's stock valued at $74,000 after purchasing an additional 725 shares during the last quarter. McIlrath & Eck LLC purchased a new stake in shares of Enovis during the fourth quarter worth $152,000. Finally, Cullen Frost Bankers Inc. bought a new position in shares of Enovis in the first quarter worth $198,000. Institutional investors own 98.45% of the company's stock.

Wall Street Analyst Weigh In

ENOV has been the subject of a number of analyst reports. Evercore ISI dropped their target price on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Canaccord Genuity Group dropped their price target on shares of Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. UBS Group decreased their price target on shares of Enovis from $65.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Needham & Company LLC dropped their target price on shares of Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Finally, Wells Fargo & Company decreased their target price on shares of Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a research report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Enovis has an average rating of "Buy" and a consensus target price of $51.00.

Enovis Price Performance

Enovis stock traded down $0.80 during mid-day trading on Friday, hitting $32.37. 1,326,522 shares of the company were exchanged, compared to its average volume of 974,899. The business has a fifty day moving average of $29.65 and a 200 day moving average of $32.54. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $1.85 billion, a PE ratio of -2.27 and a beta of 1.68. Enovis Corporation has a 1-year low of $25.47 and a 1-year high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.74 by $0.05. The firm had revenue of $564.50 million for the quarter, compared to analysts' expectations of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The business's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 EPS. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, sell-side analysts expect that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Buying and Selling

In other Enovis news, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was acquired at an average price of $29.71 per share, with a total value of $74,275.00. Following the completion of the purchase, the chief financial officer directly owned 116,729 shares of the company's stock, valued at approximately $3,468,018.59. This trade represents a 2.19% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Damien Mcdonald bought 6,457 shares of the business's stock in a transaction dated Thursday, September 11th. The stock was acquired at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the purchase, the chief executive officer directly owned 102,753 shares in the company, valued at approximately $3,182,260.41. The trade was a 6.71% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 12,157 shares of company stock valued at $374,760 over the last 90 days. Company insiders own 2.70% of the company's stock.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.